The pace of drug development can be maddeningly slow. The fact that we had our final, blockbuster results in May of 2020, and that we might not be able to start dosing for the Phase IIB until Q2 2022 -- two years later is quite honestly disgraceful and a complete disservice to the boys who suffer from this disease, most of whom only have twenty something years to live.
Ann: ATL1102 DMD Paediatric Investigation Plan submitted to EMA, page-43
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.5¢ |
Change
0.005(3.85%) |
Mkt cap ! $121.7M | |||
| Open | High | Low | Value | Volume |
| 13.5¢ | 13.5¢ | 13.0¢ | $378.0K | 2.903M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5000 | 13.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.5¢ | 516956 | 4 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |